• Gubra appointed Kristian Borbos and Zoë Johnson as co-CEOs effective November 10, 2026, replacing Markus Rohrwild, who stepped down.
• Borbos joined as chief financial officer in 2022; he previously served as CFO of Ascelia Pharma.
• Johnson joined in 2026 as head of Ventures & Business Development; she previously held the chief scientific and development officer role at Molecule to Medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.